

NMTCB Positron Emission Tomography (PET) Practice Exam (Sample)

Study Guide



Everything you need from our exam experts!

Copyright © 2025 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain from reliable sources accurate, complete, and timely information about this product.

SAMPLE

Questions

SAMPLE

- 1. Oligodendroglioma is classified as which grade of brain tumor?**
 - A. Grade 1**
 - B. Grade 2**
 - C. Grade 3**
 - D. Grade 4**
- 2. Which particle is primarily associated with alpha decay?**
 - A. Beta Particle**
 - B. Neutron**
 - C. Carbon Atom**
 - D. Helium Atom**
- 3. Which structure in the brain is associated with areas of FDG uptake in the gray matter?**
 - A. Pons**
 - B. Caudate Nucleus**
 - C. Cerebellum**
 - D. Medulla Oblongata**
- 4. What is the level of Strontium-85 at stop levels?**
 - A. 0.01 uCi/mCi**
 - B. 0.02 uCi/mCi**
 - C. 0.03 uCi/mCi**
 - D. 0.05 uCi/mCi**
- 5. What process involves the creation of two electrons, one negatively charged and one positively charged, from electromagnetic energy?**
 - A. Internal Conversion**
 - B. Photoelectric Effect**
 - C. Pair Production**
 - D. Isomeric Transition**

- 6. What is the formula for calculating the SUV body weight?**
- A. $\text{SUV} = [\text{ROI tracer concentration (mCi/cc)}] / [\text{tracer dose (mCi)/weight (kg)}]$**
 - B. $\text{SUV} = [\text{tracer dose (mCi)/weight (kg)}] / [\text{ROI tracer concentration (mCi/cc)}]$**
 - C. $\text{SUV} = [\text{tracer concentration (mCi/cc)}] + [\text{tracer dose (mCi)}]$**
 - D. $\text{SUV} = [\text{ROI tracer concentration (mCi/cc)}] * [\text{tracer dose (mCi)/weight (kg)}]$**
- 7. Which organ is the most common site for metastasis?**
- A. Brain**
 - B. Liver**
 - C. Lungs**
 - D. Bone**
- 8. What is the maximum energy of O-15?**
- A. 0.96 MeV**
 - B. 1.72 MeV**
 - C. 3.36 MeV**
 - D. 1.19 MeV**
- 9. Which isotope has the shortest half-life among O-15, N-13, and C-11?**
- A. C-11**
 - B. O-15**
 - C. N-13**
 - D. Rb-82**
- 10. Which class of medication is used to treat and prevent blood clots?**
- A. Analgesics - NSAID**
 - B. Antibiotics**
 - C. Anticoagulants**
 - D. Beta-blockers**

Answers

SAMPLE

1. B
2. D
3. B
4. B
5. C
6. A
7. D
8. B
9. B
10. C

SAMPLE

Explanations

SAMPLE

1. Oligodendroglioma is classified as which grade of brain tumor?

- A. Grade 1**
- B. Grade 2**
- C. Grade 3**
- D. Grade 4**

Oligodendroglioma is classified as a Grade 2 brain tumor. This classification is based on the World Health Organization (WHO) grading system for central nervous system tumors, which categorizes tumors based on their histological characteristics and clinical behavior. Grade 2 tumors, such as oligodendrogliomas, tend to have relatively slow growth rates and are often associated with better outcomes compared to higher-grade tumors. They may present with fewer symptoms initially, but they can still recur and progress to higher grades over time, which may necessitate treatment such as surgery, radiation, or chemotherapy. In contrast, Grade 1 tumors, like pilocytic astrocytomas, are typically benign and have the best prognosis. Grade 3 and Grade 4 tumors, such as anaplastic oligodendrogliomas and glioblastomas respectively, are more aggressive with a higher rate of recurrence and poorer prognosis. Thus, identifying oligodendroglioma as a Grade 2 tumor is essential for understanding its nature, treatment options, and prognosis.

2. Which particle is primarily associated with alpha decay?

- A. Beta Particle**
- B. Neutron**
- C. Carbon Atom**
- D. Helium Atom**

Alpha decay is a type of radioactive decay in which an unstable nucleus releases an alpha particle to become more stable. An alpha particle consists of two protons and two neutrons, which is essentially the same as a helium nucleus. Therefore, it can be correctly identified with a helium atom since the emission of an alpha particle transforms the original atom into a new element, typically resulting in a lower atomic number. In the case of alpha decay, the ejected particle (the alpha particle) is directly related to the helium atom, making it a fundamental player in this type of decay process. Thus, identifying the particle primarily associated with alpha decay as a helium atom aligns with the definition and characteristics of the alpha particle involved in the nuclear reaction.

3. Which structure in the brain is associated with areas of FDG uptake in the gray matter?

A. Pons

B. Caudate Nucleus

C. Cerebellum

D. Medulla Oblongata

The caudate nucleus is a critical part of the brain's basal ganglia system and is involved in a range of functions, including motor control, learning, and memory. Its association with areas of FDG (fluorodeoxyglucose) uptake in the gray matter is significant due to the fact that FDG PET imaging is used to assess metabolic activity in the brain. The caudate nucleus, as part of the gray matter, shows notable uptake of FDG because this region is metabolically active, reflecting the underlying neuronal activity. Higher FDG uptake indicates regions of the brain that are engaged in processing information, performing motor functions, or are otherwise active during various cognitive tasks. This is important in diagnosing and understanding neurodegenerative diseases, where abnormalities in FDG uptake patterns can indicate regions affected by conditions like Alzheimer's disease or Parkinson's disease. In contrast, while the other structures listed—pons, cerebellum, and medulla oblongata—are essential parts of the brain with their respective functions, they are typically more associated with different types of processing (such as balance, coordination, and autonomic functions) and may not demonstrate the same level of FDG uptake associated with higher cognitive and motor functions.

4. What is the level of Strontium-85 at stop levels?

A. 0.01 uCi/mCi

B. 0.02 uCi/mCi

C. 0.03 uCi/mCi

D. 0.05 uCi/mCi

Strontium-85 is a radionuclide that is used in various medical applications, particularly in the field of nuclear medicine and PET. When discussing the levels of Strontium-85 at stop levels in this context, it is important to understand that "stop levels" refer to the limits set to ensure safety and minimize exposure to radiation. The correct level of 0.02 uCi/mCi indicates the allowed concentration of Strontium-85 activity per unit of radioactivity. This limit is established based on safety guidelines to protect both patients and healthcare workers from unnecessary radiation exposure while still allowing for the effective use of the isotope in medical procedures. This value reflects regulatory standards that take into account both the benefits of using the radionuclide and the need to mitigate potential risks from radiation. Effective management of radioactive materials in clinical settings relies on adhering to these guidelines to maintain safe environments for both patients and personnel involved in nuclear medicine practices.

5. What process involves the creation of two electrons, one negatively charged and one positively charged, from electromagnetic energy?

A. Internal Conversion

B. Photoelectric Effect

C. Pair Production

D. Isomeric Transition

The process referred to in the question is pair production, which specifically describes the phenomenon where a high-energy photon, typically of electromagnetic energy, interacts with a strong electromagnetic field (often near a nucleus), resulting in the creation of a particle-antiparticle pair. In this case, the pair consists of two electrons: one with a negative charge and the other with a positive charge, known as a positron. This process requires the energy of the incoming photon to be at least equal to the rest mass energy of the electron-positron pair, which is calculated using Einstein's equation $E=mc^2$. The threshold energy for pair production of an electron and positron is approximately 1.022 MeV, considering both particles must account for their respective rest mass energy. The other options describe different interactions and are not related to the creation of the charged particle pair from electromagnetic energy. For example, internal conversion involves the transfer of energy from an excited nucleus to an electron, causing the electron to be ejected without the creation of new particles. The photoelectric effect describes the ejection of an electron from a material after absorbing a photon, also not resulting in a pair of charged particles. Isomeric transition involves the release of energy from a nucleus via gamma

6. What is the formula for calculating the SUV body weight?

A. $SUV = [ROI \text{ tracer concentration (mCi/cc)}] / [tracer \text{ dose (mCi)/weight (kg)}]$

B. $SUV = [tracer \text{ dose (mCi)/weight (kg)}] / [ROI \text{ tracer concentration (mCi/cc)}]$

C. $SUV = [tracer \text{ concentration (mCi/cc)}] + [tracer \text{ dose (mCi)}]$

D. $SUV = [ROI \text{ tracer concentration (mCi/cc)}] * [tracer \text{ dose (mCi)/weight (kg)}]$

The formula for calculating the Standardized Uptake Value (SUV) based on body weight is represented correctly in the choice. SUV is a commonly used metric in PET imaging to assess the uptake of radiotracers in tissues, normalized to the patient's body weight. The calculation helps in comparing the concentration of the radiotracer in a region of interest (ROI) to the total amount of tracer injected, adjusted for body weight, providing a standardized measure that accounts for body size. To break it down: the ROI tracer concentration measures the radioactivity concentration in a specific tissue area, while the tracer dose reflects the total amount of the radiotracer administered to the patient, divided by their weight to give a value in kg. This normalization allows for accurate assessments of metabolic activity, particularly useful in oncological evaluations. The other options do not correctly represent the standard formula for SUV concerning body weight. The essential framework is to measure the concentration in a defined volume (the ROI) against the body weight-adjusted total injected dose, ensuring that variations in body size don't skew the interpretation of the PET scan results.

7. Which organ is the most common site for metastasis?

- A. Brain
- B. Liver
- C. Lungs
- D. Bone**

The bone is the most common site for metastasis due to its highly vascularized nature and the specific biological environment it provides for cancer cells. Many types of cancer, such as breast, prostate, and lung, have a propensity to spread to the bone, where they can thrive and proliferate. The process involves the circulation of cancer cells through the bloodstream, where they can settle in the bone marrow or adjacent areas. One key reason that bone is a frequent target for metastasis is its unique microenvironment, which includes factors that can promote tumor growth, such as the presence of growth factors and signaling molecules that facilitate the survival of the metastatic cells. Additionally, certain cancers have specific affinities for bone tissue due to molecular interactions that allow the cancer cells to attach and invade bone matrices. While the brain, liver, and lungs are also common sites for metastasis in various cancers, bone is particularly notable for its high incidence. The degree of bone involvement often reflects the aggressiveness of the disease and can have significant implications for treatment decisions and patient prognosis.

8. What is the maximum energy of O-15?

- A. 0.96 MeV
- B. 1.72 MeV**
- C. 3.36 MeV
- D. 1.19 MeV

Oxygen-15 (^{15}O) is a positron-emitting radionuclide commonly used in positron emission tomography (PET). The maximum energy of any positron-emitting isotope is typically associated with the energy released during the positron emission decay process. For ^{15}O , it undergoes beta-plus decay, emitting a positron and producing nitrogen-15 as a result. The maximum energy associated with the positron emitted during this decay is 1.72 MeV. This energy is significant because it influences the range and penetration of the emitted positrons in tissue, which is an important consideration in PET imaging. Understanding the energy levels of isotopes like ^{15}O is crucial in the context of PET because the choice of radionuclide impacts image quality, resolution, and the overall effectiveness of the imaging procedure. The higher the energy of the emitted positron, the farther it can travel before annihilating with an electron, which can affect the signal received and the spatial resolution of the imaging results.

9. Which isotope has the shortest half-life among O-15, N-13, and C-11?

A. C-11

B. O-15

C. N-13

D. Rb-82

Oxygen-15 is known for its very short half-life of approximately 2 minutes. This characteristic makes it particularly useful in positron emission tomography (PET) as a radiotracer for imaging. The rapid decay allows for quick imaging processes, providing timely diagnostic information while minimizing the patient's exposure to radiation. In contrast, Carbon-11 has a longer half-life of about 20 minutes, which, while still short, allows for a broader window during which imaging can be conducted. Nitrogen-13 has a half-life of approximately 10 minutes, which is also longer than that of Oxygen-15. When choosing a radiotracer for PET, the half-life is a crucial factor because it influences the timing and logistics of imaging procedures and how the tracers distribute and decay in the body. Thus, Oxygen-15 stands out as having the shortest half-life among the isotopes listed, making it a critical option in rapid imaging protocols.

10. Which class of medication is used to treat and prevent blood clots?

A. Analgesics - NSAID

B. Antibiotics

C. Anticoagulants

D. Beta-blockers

Anticoagulants are a specific class of medications that play a vital role in treating and preventing the formation of blood clots in the bloodstream. These drugs, which include warfarin, heparin, and newer agents such as direct oral anticoagulants (DOACs), work by interfering with the blood clotting process. They achieve this by inhibiting various factors in the coagulation cascade, which is responsible for the formation of clots that can lead to conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. Anticoagulants are specifically designed to make blood flow more freely by reducing the ability of the blood to clot, which is crucial for patients at risk of clotting disorders. They are commonly used in a range of situations where the risk of clot formation is higher, such as post-surgery, in patients with atrial fibrillation, or in those with certain types of heart disease. In comparison to the other classes of medications mentioned, analgesics (particularly NSAIDs) are primarily used for pain relief, antibiotics combat bacterial infections, and beta-blockers are used for managing hypertension and certain heart conditions. None of these classes have a direct role in treating or preventing blood clots,